Endoscopic ultrasound role in pancreatic adenocarcinoma treatment: A review focusing on technical success, safety and efficacy

Table 3 Human studies reporting endoscopic ultrasound-guided fiducial markers placement, -brachytherapy and -celiac plexus neurolysis

Ref.	Study design	Cancer stage	EUS-guided intervention	Patients No.	Technical success (%)	Median overall survival (mo)	Pain palliation (patients %)	Serious adverse events, n
Pishvaian et al[48], 2006	Prospective	Unresectable	FMP	7	85.7	-1	Not reported	0
Choi et al[49], 2014	Prospective	Unresectable	FMP	29	100	-1	Not reported	12
Varadarajulu et al[50], 2010	Prospective	III (n = 9)	FMP	9	100	Not reported	Not reported	0
Park et al[51], 2010	Prospective	III (n = 57)	FMP	57	94	-1	Not reported	0
Sanders et al[52], 2010	Prospective	III (n = 36); Recurrent (n = 15)	FMP	51	90	-1	Not reported	12
Dávila et al[53], 2014	Prospective	II (n = 1); III (n = 22)	FMP	23	100	-1	Not reported	0
Khashab et al[54], 2012	Retrospective	III (n = 39)	FMP	39	100	-1	Not reported	0
Sun et al[57], 2012	Prospective	III (n = 8)	Brachytherapy	8	100	8.3	50 at week 33	0
Sun et al[58], 2006	Prospective	III (n = 8); IV (n = 7)	Brachytherapy	15	100	10.6	30 at week 42	33
Jin et al[59], 2008	Prospective	II (n = 4); III (n = 10); IV (n = 8)	Brachytherapy	22	100	9	81.8 at week 1	0
Sun et al[60], 2017	Retrospective	III (n = 18); IV (n = 24)	Brachytherapy	42	100	9	Not reported	0
Wiersema et al[62], 1996	Prospective	Unresectable	CPN	29	100	Not reported	86 at week 2; 84 at week 4; 79 at week 8; 88 at week 12	0
Levy et al[64], 2019	Prospective	II (n = 2); III (n = 27); IV (n = 31)	CPN	60	100	10.46	40.4 at week 12	0
Seicean et al[65], 2013	Prospective	Unresectable	CPN	32	100	Not reported	75 at week 2	0
Facciorusso et al[31], 2017	Prospective	III (n = 48); IV (n = 10)	CPN	58	100	6.5	70.6 at week 2	0

¹Feasibility studies not aimed to assess impact on overall survival.

²Pancreatitis supportively treated (1 patient).

³Pancreatitis complicated with pseudocyst formation (3 patients).

FMP: Fiducial markers placements; CPN: Celiac plexus neurolysis; EUS: Endoscopic ultrasound.